SCHEMBL6701806

SCHEMBL6701806

O=C1NC(=O)C(C(O)c2ccc(Cl)c(F)c2)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 4/20 0.35
WDR77 Q9BQA1 3/20 0.35
CNR1 P21554 1/20 0.34
SLC6A2 P23975 6/20 0.34
SLC6A4 P31645 6/20 0.34
SLC6A3 Q01959 6/20 0.34
S1PR1 P21453 3/20 0.34
S1PR3 Q99500 3/20 0.34
KCNH2 Q12809 2/20 0.34
ADAMTS5 Q9UNA0 2/20 0.33
MMP2 P08253 1/20 0.33
MMP14 P50281 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTGER3 P43115 1/20 0.32
GPR139 Q6DWJ6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6702888 0.77 HSD17B2 (0.41) SLC6A2SLC6A4ADAMTS5
SCHEMBL6791191 0.77 MMP2 (0.35) ADAMTS5MMP2TDP1
SCHEMBL6800602 0.75 TDP1 (0.45) ADAMTS5TDP1PTGER3
SCHEMBL6703699 0.73 BACE1 (0.32) TDP1
SCHEMBL6702161 0.72 CES2 (0.41) ADAMTS5MMP2
SCHEMBL10620249 0.72 ALDH1A1 (0.41)
SCHEMBL6702754 0.71 CES2 (0.45) SLC6A2SLC6A4
SCHEMBL6786610 0.71 HSD17B2 (0.40)
SCHEMBL6798684 0.71 HSD17B2 (0.40)
SCHEMBL6798968 0.71 HSD17B2 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040116486-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-17 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370535-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074749-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PRMT5 1720/4885WDR77 2220/4885CNR1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.